Logo
B

BioInvent International AB

146 employees

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.

Investor insights

Funding rounds participated in

$3M sweet spot round size

Investor type

Public Company

Basic info

Industry

Biotechnology

Sectors

Biotechnology

Funding rounds raised

Total raised

$3M

from investors over 1 rounds

B

BioInvent International AB raised $3M on May 26, 2023

FAQ